SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
Healthcare
$2.91 -0.53%
-$0.02 today
- Market cap
- $262.16M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
52W Low $1.85High $5.15
Volume 1.75M
Average 0.76M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$48.95M
FY 2025 · Annual
Net Income
$13.27M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 60.88M | 23.9M | 2.24M | 1.32M | 0 |
| Cost of Revenue | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| Gross Profit | 59.22M | 20.61M | (1.51M) | (3.47M) | (3.08M) |
| Gross Margin | 97.3% | 86.2% | -67.3% | -262.4% | — |
| Research & Development | 57.18M | 36.44M | 16.52M | 30.16M | 34.35M |
| Selling, General & Admin | 17.09M | 16.38M | 23.8M | 9.28M | 14.6M |
| Operating Expenses | 72.62M | 49.53M | 36.57M | 39.44M | 45.87M |
| Depreciation & Amortization | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| EBITDA | (15.2M) | (15.12M) | (38.13M) | (28.99M) | 16.6M |
| EBITDA Margin | -25.0% | -63.3% | -1703.1% | -2192.5% | — |
| Operating Income | (13.39M) | (28.92M) | (38.08M) | (42.91M) | (48.95M) |
| Operating Margin | -22.0% | -121.0% | -1700.5% | -3244.9% | — |
| Interest Income | 23.12K | 71.07K | 584.97K | 1.29M | 1.43M |
| Interest Expense | 294.46K | 301.58K | 315.28K | 318.4K | 240.66K |
| Other Income / Expenses | (3.75M) | 10.2M | (4.12M) | 8.81M | 62.23M |
| Income Before Tax | (17.15M) | (18.72M) | (42.19M) | (34.11M) | 13.27M |
| Pre-Tax Margin | -28.2% | -78.3% | -1884.5% | -2579.0% | — |
| Income Tax Expense | 0 | 25.63K | 0 | 0 | 0 |
| Net Income | (17.15M) | (18.74M) | (42.19M) | (34.11M) | 13.27M |
| Net Margin | -28.2% | -78.4% | -1884.5% | -2579.0% | — |
| EPS (Basic) | (3.94) | (4.31) | (7.64) | (3.68) | 0.22 |
| EPS (Diluted) | (6.30) | (4.31) | (7.64) | (3.68) | (0.79) |
| 4.35M | 4.35M | 5.52M | 9.26M | 19.31M | |
| 2.73M | 4.35M | 5.52M | 9.26M | 61.34M |
SABS Earnings Waterfall · TTM
NASDAQ:SABS · Revenue to Net Income
Key Ratios
EPS$-0.86
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$12.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.86, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 25-NSE | 25-NSE filing | Oct 22, 2026 | |
| 8-K | Current report | Oct 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 | |
| 424B3 | 424B3 filing | Aug 21, 2026 |
How much revenue does SABS generate?
SAB Biotherapeutics, Inc. (SABS) reported $0.00 of revenue in fiscal 2025.
Is SABS profitable?
SAB Biotherapeutics, Inc. (SABS) reported $13.27M of net income.
Continue the stock analysis
Jump to another research area for this company.